PPAR-gamma agonist pioglitazone modifies craving intensity and brain white matter integrity in patients with primary cocaine use disorder: a double-blind randomized controlled pilot trial.

Background and aims Pioglitazone (PIO), a potent agonist of PPAR-gamma, is a promising candidate treatment for cocaine use disorder (CUD). We tested the effects of PIO on targeted mechanisms relevant to CUD: cocaine craving and brain white matter (WM) integrity. Feasibility, medication compliance an...

Descripción completa

Detalles Bibliográficos

Publicado en:	Addiction Vol. 112; no. 10; pp. 1861 - 1869
Autores principales:	Schmitz, Joy M., Green, Charles E., Hasan, Khader M., Vincent, Jessica, Suchting, Robert, Weaver, Michael F., Moeller, F. Gerard, Narayana, Ponnada A., Cunningham, Kathryn A., Dineley, Kelly T., Lane, Scott D.
Formato:	research tables/charts randomized controlled trial Journal Article
Publicado:	Wiley-Blackwell Oct2017
Acceso en línea:	Ver este registro en EBSCOhost